Po-Pang Chen

Po-Pang Chen

Auto-generated profile, based on publicly available information

Po-Pang Chen

Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
PCPo-Yin Chen
Po-Yin Chen
YCYung-Chih Chen
Yung-Chih Chen
PCPo-Pang Chen
Po-Pang Chen
KLKuan-Ting Lin
Kuan-Ting Lin
KSKaren Sargsyan
Karen Sargsyan
STSee-Yeun Ting
See-Yeun Ting
Developing programmable bacterial cell-cell adhesion is of significant interest due to its versatile applications. Current methods that rely on presenting cell adhesion molecules (CAMs) on bacterial surfaces are limited by the lack of a generalizable strategy to identify such molecules targeting bacterial membrane proteins in their natural states. Here, we introduce a whole-cell screening platform designed to discover CAMs targeting bacterial membrane proteins within a synthetic bacteria-displayed nanobody library. Leveraging the potency of the bacterial type IV secretion system—a contact-dependent DNA delivery nanomachine—we have established a positive feedback mechanism to selectively enrich for bacteria displaying nanobodies that target antigen-expressing cells. Our platform successfully identified functional CAMs capable of recognizing three distinct outer membrane proteins (TraN, OmpA, OmpC), demonstrating its efficacy in CAM discovery. This approach holds promise for engineering bacterial cell-cell adhesion, such as directing the antibacterial activity of programmed inhibitor cells toward target bacteria in mixed populations.

10 June 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
HYHung-Wei Yeh
Hung-Wei Yeh
PCPo-Pang Chen
Po-Pang Chen
TYTzu-Chen Yeh
Tzu-Chen Yeh
SLShiou-Lan Lin
Shiou-Lan Lin
YCYue-Ting Chen
Yue-Ting Chen
HCHui-Chun Cheng
Hui-Chun Cheng
Human Cep57 is a coiled-coil scaffold at the pericentriolar matrix (PCM), controlling centriole duplication and centrosome maturation for faithful cell division. Genetic truncation mutations of Cep57 are associated with the mosaic-variegated aneuploidy (MVA) syndrome. During interphase, Cep57 forms a complex with Cep63 and Cep152, serving as regulators for centrosome maturation. However, the molecular interplay of Cep57 with these essential scaffolding proteins remains unclear. Here, we demonstrate that Cep57 undergoes liquid–liquid phase separation (LLPS) driven by three critical domains (NTD, CTD, and polybasic LMN). In vitro Cep57 condensates catalyze microtubule nucleation via the LMN motif-mediated tubulin concentration. In cells, the LMN motif is required for centrosomal microtubule aster formation. Moreover, Cep63 restricts Cep57 assembly, expansion, and microtubule polymerization activity. Overexpression of competitive constructs for multivalent interactions, including an MVA mutation, leads to excessive centrosome duplication. In Cep57-depleted cells, self-assembly mutants failed to rescue centriole disengagement and PCM disorganization. Thus, Cep57’s multivalent interactions are pivotal for maintaining the accurate structural and functional integrity of human centrosomes.

14 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAthira Saju
Athira Saju
PCPo-Pang Chen
Po-Pang Chen
TWTzu-Han Weng
Tzu-Han Weng
STSu-Yi Tsai
Su-Yi Tsai
ATAkihiro Tanaka
Akihiro Tanaka
KHKuo-Chiang Hsia
Kuo-Chiang Hsia
Vinca alkaloids, a class of tubulin-binding agent, are widely used in treating cancer, yet the emerging resistance compromises their efficacy. Hepatoma up-regulated protein (HURP), a microtubule-associated protein displaying heightened expression across various cancer types, reduces cancer cells’ sensitivity to vinca-alkaloid drugs upon overexpression. However, the molecular basis behind this drug resistance remains unknown. Here we discover a tubulin-binding domain within HURP, and establish its role in regulating microtubule growth. Cryo-EM analysis reveals interactions between HURP’s tubulin-binding domain and the vinca domain on β-tubulin -- the site targeted by vinca alkaloid drugs. Importantly, HURP competes directly with vinorelbine, a vinca alkaloid-based chemotherapeutic agent, countering microtubule growth defects caused by vinorelbine both in vitro and in vivo. Our findings elucidate a mechanism driving drug resistance in HURP-overexpressing cancer cells and emphasize HURP tubulin-binding domain’s role in mitotic spindle assembly. This underscores its potential as a therapeutic target to improve cancer treatment.

16 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
TWTzu-Han Weng
Tzu-Han Weng
YPYu-Chung Pien
Yu-Chung Pien
CCChing-Jou Chen
Ching-Jou Chen
PCPo-Pang Chen
Po-Pang Chen
YTYu-Ting Tseng
Yu-Ting Tseng
STSu-Yi Tsai
Su-Yi Tsai
Proper regulation of glycogen metabolism is fundamental to cellular energy homeostasis, and its disruption is associated with various metabolic disorders, including glycogen storage diseases (GSDs) and potentially diabetes. Despite glycogen’s role as an essential energy reservoir, the mechanisms governing its synthesis and structural diversity across tissues remain unclear. Here, we uncover the distinct physiological roles of the human glycogenins GYG1 and GYG2 in glycogen synthesis. Through cellular models, structural biology, and biochemical analyses, we demonstrate that, unlike GYG1, GYG2 exhibits minimal autoglycosylation activity and acts as a suppressor of glycogen formation. Together, these two glycogenins coordinate glycogen synthase activity and influence glycogen assembly in a cell-type-dependent manner. Importantly, these glycogenins modulate glucose metabolic pathways, thereby ensuring cellular glucose homeostasis. These findings address longstanding questions in glycogen metabolism and establish both GYG1 and GYG2 as critical regulators of glycogen synthesis and breakdown in human, providing insights with potential therapeutic implications for treating GSDs and metabolic diseases.